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Abstract:  
 
Title: Patterns of prescribing in the management of gastro-oesophageal reflux in infants 
aged 0 to 1 year in Scotland. 
 
Objective: To determine trends over time and geographical differences in prescribing for 
gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) in infants 
aged 0 to 1 year in Scotland. 
 
Methods: National prescribing data obtained from the Information Services Division of NHS 
Scotland (ISD Scotland) was quantitatively analysed using the software tool Minitab16 
 
Results: Prescribing of the three key medicines, alginate, omeprazole and ranitidine, used in 
the management of GOR and GORD in infants aged 0 to 1 year increased in Scotland over 
the 7 years between 2010 and 2016. Although the prescribing for alginate showed the 
greatest absolute increase rising from 15.7% in 2010 to 24.7% in 2016, the prescribing rate 
for ranitidine increased four-fold and for omeprazole three-fold. The data also showed 
much variation in the patterns of prescribing across NHS Boards.  
 
Conclusions: The rise in the prescribing rates of alginate, omeprazole and ranitidine is a 
cause for concern given the uncertainty regarding the efficacy of these medicines in this age 
group and that omeprazole and ranitidine are not licensed for use in infants under one year 
of age in the UK. While the data suggest that the prescribing rate of alginate may have 
stabilised, the increasing trends for omeprazole and ranitidine show no sign of abating and 
this may have financial implications for the NHS as well as potential ethical and health 
implications for young infants. 
 
Keywords: Regurgitation; Gaviscon, Ranitidine, Omeprazole 
 
What is already known? 
 The use of pharmaceutical products to manage GOR has increased in some countries 
 Evidence supporting the use of medicines in the management of GOR are equivocal 
 Ranitidine and omeprazole are not yet licensed for use in infants under 1 year old 
age. 
 
What this study adds? 
 There is an increasing use of alginate (Gaviscon), ranitidine (H2RA) and omeprazole 
(PPI) in the management of symptoms of GOR/ GORD in Scotland. 
 There is regional variation in the use of these medicines to management symptoms 
of GOR 
 Practitioners may not follow the stepped care approach advocated by NICE (2015) 
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Introduction 
 
Anecdotal evidence from discussions with health visitors suggests an increase in the 
diagnosis and prescribing for gastro-oesophageal reflux (GOR) in Scotland.  Furthermore, 
evidence suggests that the use of pharmaceutical products to manage symptoms of GOR in 
infants is increasing internationally (Barron et al, 2007, Khoshoo et al, 2007, Rimmer and 
Hiscock, 2013; De Bruyne et al, 2014) and is not just a Scottish issue. A large retrospective 
observational study (Barron et al, 2007) undertaken in the United States found the use of 
proton pump inhibitors (PPI) increased four-fold between 2000 and 2003. In Belgium a 
retrospective observational study (De Bruyne et al, 2014) found a seven-fold increase in 
prescribing of all anti-reflux medicines between 1997 and 2009, but the increase was most 
significant in the prescribing of H2 receptor antagonists (H2RA) and PPIs. Interestingly an 
Australian study (Rimmer and Hiscock, 2013) that focused on crying infants suggests that in 
Australia some paediatricians are misdiagnosing the problem of crying in infants, resulting in 
GOR and gastro-oesophageal reflux disease (GORD) being over-diagnosed and leading to 
inappropriate prescribing of PPIs. A more recent cross-sectional survey (Kirby et al, 2016) 
however, explored the attitudes and practices of 400 general practitioners in Australia and 
found a high percentage (87%) of general practitioners in the study prescribed H2RAs and 
PPIs to infants with symptoms of GOR.  This study, therefore, sought to examine current 
data held by the Information Services Division of NHS Scotland (ISD Scotland) in order to 
assess the validity of this anecdotal evidence and to determine overall trends and regional 
differences in prescribing for GOR in infants in Scotland. The Information Services Division of 
NHS Scotland (ISD Scotland) is part of National Services Scotland (NSS) and provides the 
national statistical data that informs decision making and planning in the National Health 
Service (NHS) in Scotland (ISD Scotland, 2010). 
 
 
Methods 
 Prescribing data for the key medicines used to manage GOR and GORD in the 0 to 1-
year age group for the whole of Scotland, and across all 14 NHS Boards, for the seven-year 
period from 2010 and 2016 (inclusive) were obtained from ISD Scotland to identify patterns 
of prescribing. Data prior to 2010 were not available due to different methods of recording 
data. For the purposes of this study, the age range of infants prescribed medicine was 
restricted to 0 to 1 year because ISD Scotland record prescribing rates in whole year age 
groups. More detailed data regarding the age in months of infants was not available. The 
data gathered include the number of items dispensed and paid for, the patient count, and 
the prescribing rate for the key medicines used to manage GOR and GORD in Scotland and 
the UK: Gaviscon (Alginate), ranitidine (H2RA), omeprazole (PPI).  
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Data Analysis 
Secondary analysis of the data was then undertaken to explore the objectives of this study. 
The software tool, Minitab 16, was used to manage and analyse the data obtained 
concerning the 14 NHS Boards in Scotland. In addition to graphical comparisons, confidence 
intervals were constructed to provide an indication of the precision of the rates and linear 
regression analysis was used to assess apparent trends. 
The population sizes for Scotland and the NHS boards for the study period were reviewed 
and it was noted that the population sizes in Orkney, Shetland and the Western Isles are 
relatively low. Hence, relatively wide confidence intervals are computed for these boards 
which reflect the lower precision associated with their rates. In a few particular instances 
where the number of prescriptions was very low (<10), confidence intervals would be 
considered invalid and, thus, were not constructed. However, these instances do not 
feature amongst the particular results highlighted in this paper. 
 
 
Results  
The data reveal that across the whole of Scotland, the prescribing rate for all three 
medicines increased during the seven years between 2010 and 2016. Evidently, the 
prescribing rate for alginate was persistently much higher than for the other pharmaceutical 
products used in the management of GOR and GORD in infants (Table 1).  
 The higher rate in alginate prescribing is not unexpected as it reflects NICE (2015) 
guidance that recommends a two-week trial of alginate therapy in breastfed babies. It is 
also in line with the stepped-care approach applied to formula fed babies that have shown 
no improvement following the introduction of a thickened formula.  
 Although the prescribing rate for alginate shows the greatest absolute increase, from 
15.7% in 2010 to 24.7% in 2016, the prescribing rate for ranitidine increased over four-fold 
from 2.3% in 2010 to 9.7% in 2016, and for omeprazole it increased over three-fold from 
0.9% in 2010 to 3.2% in 2016. It is also interesting to note that whilst the prescribing rates 
for both omeprazole and ranitidine have risen steadily, the prescribing rate for alginate 
began to level out from 2014. Confidence intervals for the ‘true’ prescribing of alginate, 
omeprazole and ranitidine are also presented in Table 1. The intervals are typically narrow 
and confirm that perceived differences over time cannot be attributed to random 
fluctuation. 
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Table 1: Prescribing rate and 95% Confidence Intervals for Scotland 2010 – 2016. 
 
Prescribing rate, Lower & Upper Confidence Intervals (CI) in Scotland 2010 – 
2016 
Year Alginate Omeprazole Ranitidine 
2010 
 
15.75% 
(15.43 - 16.07) 
0.89% 
(0.81 - 0.96) 
2.33% 
(2.21 - 2.45) 
2011 18.20% 
(17.85 - 18.54) 
1.19% 
(1.11 - 1.28) 
3.02% 
(2.88 - 3.16) 
2012 19.67% 
(19.31 - 20.02) 
1.40% 
(1.30 - 1.49) 
3.6% 
(3.51 - 3.82) 
2013 21.97% 
(21.59 - 22.35) 
1.85% 
(1.74 - 1.96) 
4.97% 
(4.78 - 5.15) 
2014 24.28% 
(23.87 - 24.68) 
2.49% 
(2.36 - 2.62) 
6.83% 
(6.61 - 7.04) 
2015 24.80% 
(24.39 - 25.20) 
2.86% 
(2.72 - 3.00) 
8.17% 
(7.94 - 8.41) 
2016 24.72% 
(24.31 - 25.13) 
3.26% 
(3.11 - 3.41) 
9.66% 
(9.40 - 9.92) 
 
 
The data were further analysed to examine the prescribing pattern for the three drugs in 
each of the 14 NHS Boards in Scotland. The prescribing rates for omeprazole and ranitidine 
in each NHS Board from 2010 and 2016 are illustrated in Figures 1, and 3. The prescribing 
rates of these medicines were ranked and the top three ranking NHS Boards for all three 
medicines between 2010 -2016 are presented in Table 2.  
 There is clear variation in the pattern of prescribing for each drug, across the NHS 
Boards with different boards featuring amongst the top ranks for each drug.  For alginate 
Lanarkshire features in the top three ranks in all but one of seven years and is ranked 
highest in 2016. While the prescribing rates of alginate appear to have stabilized at other 
high-prescribing boards, the Lanarkshire rate has continued to increase approximately 
linearly and over the full study period from 19.08% to 32.48%. Forth Valley features in the 
top three ranks for each year apart from 2016; in fact, the rate dropped in each of the last 
two study years. At Greater Glasgow and Clyde, the alginate prescribing rate increased 
sharply from 17.05% in 2010 to 30.11% in 2015, and despite a reduction to 27.78% in 2016 
still held second top ranking. Grampian was initially the highest prescriber of alginate but 
does not appear in the top 3 ranks after 2013. The increase at Grampian from 2010 to 2016 
of 3.86% is relatively low.    
 Lothian, Dumfries and Galloway, Fife and Lanarkshire were found to have the highest 
prescribing rates for omeprazole. The prescribing rate for omeprazole showed an increasing 
trend in each of these boards over the study period with Lothian top-ranked in each of the 
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seven years, rising from 1.76% to 5.65%. In Dumfries and Galloway, the prescribing rate for 
omeprazole rose sharply in 2016 to 5.4%, almost level with Lothian.  
 With regard to ranitidine, over the full study period Grampian clearly had the highest 
prescribing rate, rising linearly from 4.87% to 14.35%. Forth Valley and Shetland also feature 
consistently near the top of the Ranitidine rankings. (Whilst the individual confidence 
intervals for Shetland are relatively wide due to relatively small population numbers, the 
cumulative evidence over the study period is substantial).  
 It is also interesting that, in contrast to having one of the highest prescribing rates 
for omeprazole, Dumfries and Galloway has the second lowest prescribing rate in the 
mainland boards for ranitidine. Conversely, Grampian has the highest prescribing rate for 
ranitidine but the second lowest mainland board prescribing rate for omeprazole. 
Compared to most of the other Boards, Ayr and Arran had low prescribing rates for all three 
drugs over the study period although these still showed underlying increasing trends. 
 
 
 
Figure 1: Prescribing rate of omeprazole by NHS Board 
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Figure 2: Prescribing rate of ranitidine by NHS Board 
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Table 2. Ranking of the NHS Boards with the highest prescribing rates for alginate, 
omeprazole and ranitidine (2010 – 2016) 
 
 Alginate Omeprazole Ranitidine 
Rank 1 
(Highest) 
Rank 2 Rank 3 Rank 1 
(Highest) 
Rank 2 Rank 3 Rank 1 
(Highest) 
Rank 2 Rank 3 
2010 
Rate (per 100) 
(Lower - Upper 
CI) 
Grampian 
20.16 
(19.17 - 
21.14) 
Lanarkshire 
19.08. 
(18.14 - 
20.02) 
Forth Valley 
17.62 
(16.34 - 
18.91) 
Lothian  
1.76 
(1.50 - 
2.02) 
Lanarkshire 
1.56 
(1.26 - 1.86) 
Fife 
1.40 
(1.04 - 1.76) 
Grampian 
5.43 
(4.85 – 
6.00) 
Shetland 
4.80 
(2.19 - 
7.40) 
Forth 
Valley 
3.78 
(3.13 - 
4.44) 
2011 
Rate (per 100) 
(Lower - Upper 
CI) 
Grampian 
22.53 
(21.51 - 
23.54) 
Lanarkshire 
21.40 
(20.40 - 
22.39) 
Forth Valley 
19.87 
(18.54 - 
21.20) 
Lothian  
2.59 
(2.27 - 
2.91) 
Lanarkshire 
1.64 
(1.33 - 1.95) 
Fife 
1.53 
(1.16 - 1.91) 
Grampian 
7.33 
(6.67 - 7.99) 
Shetland 
4.30 
(1.87 - 
6.73) 
Forth 
Valley 
3.89 
(3.24 - 
4.55) 
2012 
Rate (per 100) 
(Lower - Upper 
CI) 
Forth 
Valley 
24.31 
(22.83 - 
25.80) 
Grampian 
23.58 
(22.55 - 
24.61) 
Lanark 
23.35 
(22.33 - 
24.38) 
Lothian  
2.98 
(2.65 - 
3.31) 
Lanarkshire 
1.88 
(1.55 - 2.21) 
Dumfries & 
Galloway 
1.77 
(1.10 - 2.44) 
Grampian 
8.43 
(7.73 - 9.14) 
Forth 
Valley 
4.63 
(3.88 - 
5.37) 
Shetland 
4.30 
(1.87 - 
6.73) 
2013 
Rate (per 100) 
(Lower - Upper 
CI) 
Forth 
Valley 
25.69 
(24.20 - 
27.17) 
Gt Glasgow 
& Clyde 
25.18 
(24.44 - 
25.93) 
Grampian 
24.67 
(23.61 - 
25.73) 
Lothian  
4.24 
(3.84 - 
4.65) 
Dumfries & 
Galloway 
2.78 
(1.90 - 3.67) 
Lanarkshire 
2.30 
(1.96 - 2.65) 
Grampian 
10.46 
(9.70 - 
11.21) 
Shetland 
8.56 
(4.98 – 
12.14) 
Forth 
Valley 
5.70 
(4.89 - 
6.51) 
2014 
Rate (per 100) 
(Lower - Upper 
CI) 
Gt Glasgow 
& Clyde 
27.60 
(26.83 - 
28.37) 
Forth Valley 
27.29 
(25.72 - 
28.86) 
Lanarkshire 
25.95 
(24.93 - 
26.97) 
Lothian 
4.92 
(4.48 - 
5.36) 
Dumfries & 
Galloway 
3.80 
(2.76 - 4.83) 
Fife 
3.27 
(2.71 - 3.84) 
Grampian 
12.16 
(11.35 – 
12.97) 
Forth 
Valley 
9.08 
(8.01 - 
10.14) 
Orkney 
9.04 
(4.87 - 
13.22) 
2015 
Rate (per 100) 
(Lower - Upper 
CI) 
Gt Glasgow 
& Clyde 
30.11 
(29.31 - 
30.91) 
Lanarkshire 
29.96 
(28.88 - 
31.04) 
Forth Valley 
25.07 
(23.53 - 
26.62) 
Lothian  
5.49 
(5.02 - 
5.96) 
Fife 
3.34 
(2.76 - 3.91) 
Dumfries & 
Galloway 
3.25 
(2.27 - 4.23) 
Grampian 
12.14 
(11.34 - 
12.94) 
Forth 
Valley 
10.44 
(9.35 - 
11.53) 
Highland 
9.80 
(8.67 - 
10.93) 
2016 
Rate (per 100) 
(Lower - Upper 
CI) 
Lanarkshire 
32.48 
(31.40 - 
33.57) 
Gt Glasgow 
& Clyde 
27.78 
(26.99 - 
28.56) 
Shetland 
26.89 
(21.26 – 
32.52) 
Lothian  
5.65 
(5.17 - 
6.13) 
Dumfries & 
Galloway 
5.42 
(4.15 - 6.69) 
Fife 
3.84 
(3.22 - 4.46) 
Shetland 
14.71 
(10.21 - 
19.20) 
Grampian 
14.35 
(13.48 - 
15.22) 
Forth 
Valley 
11.83 
(10.68 - 
12.98) 
 
 
 
Discussion 
The results show an estimated annual increase in rate of 1.60 percentage points per year in 
the use of alginate, 1.27 in the use of ranitidine, and 0.41 in the use of omeprazole in infants 
aged 0-1 year in Scotland over the seven years from 2010 to 2016. This outcome mirrors the 
findings of previous studies undertaken in United States (between 1999 and 2004 in respect 
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of PPI use) and Belgium (between 1997 and 2009 concerning acid suppressant medication) 
that reported an increase in the use of PPIs and H2RAs in infants aged 0 to 1 year (Barron et 
al, 2007; De Bruyne et al, 2014). This study, however, has also highlighted significant 
regional variation in the pattern of prescribing of alginate, omeprazole and ranitidine in 
Scotland. The reason for the regional variation is unclear but may be linked with the 
alignment of NHS Boards to major paediatric centres, such as Glasgow, Edinburgh, and 
Aberdeen and their associated protocols and prescribing preferences, or to local guidelines 
and recommended practices in each NHS Board area. Other possible reasons for the 
variation in prescribing rates may relate to regional differences in affluence or deprivation, 
or the accessibility of health services, however further research is needed to provide more 
definitive answers. Given the current deficit in the number of health visitors and general 
practitioners working in Scotland (Scottish Government, 2014, ISD Scotland, 2016) the 
variation in prescribing rates may also be associated with staffing levels in NHS Boards and 
the availability of these health professionals, particularly health visitors, to provide 
adequate support with the recommended conservative management of symptoms of GOR 
to concerned and anxious parents.  
 A key factor may relate to the subjective nature of diagnosis and the lack of robust 
criteria to distinguish between a diagnosis of GOR and GORD (NICE, 2015). NICE (2015) 
defines GORD as symptoms of GOR that are severe enough to merit medical treatment, 
however the notion of ‘severe enough’ is subjective and open to interpretation with no 
clear delineation between GOR and GORD. Furthermore, infants cannot describe or 
communicate the extent of the discomfort of the symptoms of GOR, therefore the severity 
of the regurgitation and discomfort will be conveyed by the parents who, caring for the 
child, and being concerned about the impact on the baby’s health and wellbeing may 
perceive the regurgitation and posseting to be ‘severe enough’ to merit medical treatment 
(Orenstein, 2010).  
 Whilst the lack of clarity regarding diagnosis may have led to the over-diagnosis or 
misdiagnosis of GOR and GORD, it could also be argued that in recent years, diagnosis has 
improved resulting in more cases of GOR and GORD now being identified. This may be an 
explanation for the rise in prescribing of alginate, omeprazole and ranitidine in infants. 
Alternatively, it has been questioned whether the identified symptoms of GOR can actually 
be attributed to GOR and not another cause (NICE, 2015). For example, symptoms of cows 
milk protein allergy and lactulose intolerance are akin to that of GOR and GORD, further 
adding to the complexity of forming a diagnosis (Onyeador, Paul, and Sandhu, 2014; NICE, 
2015, BNF For Children, 2016). However, whilst evidence suggests that 2% to 6% of children 
suffer from cows milk protein allergy, which, like GOR, is most prevalent in children aged 0 
to 1 year, evidence regarding lactulose intolerance in young infants is lacking (Caffarelli et al, 
2010; NICE, 2011). 
 Nevertheless, GOR is a normal physiological event affecting over 40% of infants 
(Vandenplas et al, 2009; Tighe et al, 2014; NICE, 2015). Therefore, the increase in the 
prescribing rate of omeprazole or ranitidine coupled with the evidence of poor efficacy of 
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these medicines suggests that some infants are treated for symptoms of GOR/GORD when 
their symptoms are benign. This is a concern, particularly as these drugs are not yet licensed 
for use in infants under 1 year old and adverse effects associated with the use of some 
H2RA and PPI in older children have been reported (Kierkus et al, 2014; Gieruszczak-Bialek, 
2015). 
 The interpretation, diagnosis and treatment of normal physiological conditions as 
medical problems requiring treatment raises questions about the medicalisation of GOR. 
Reflecting on the sociology of diagnosis, Jutel (2011) highlights the prerequisites for a 
condition to become recognised as a disease are that it is undesirable and visible. This may 
be the case with GOR in infants as regurgitation, posseting, crying and unsettledness are not 
only visible but may be perceived by parents and practitioners as unpleasant, undesirable 
and disagreeable. Arguably this could be a possible explanation for the potential differential 
diagnosis and increasing use of medicines in the management of symptoms of GOR.  
  Another influence may stem from the iterative relationship between medicalisation 
and diagnosis that is continually evolving (Jutel, 2011). The concepts of diagnosis and 
medicalisation are inherently linked, nevertheless they are also very different in that 
entwined within medicalisation is the concept of pharmaceuticalisation (Williams, Gabe, 
and Davis, 2008;  Williams, Martin, and Gabe, 2011). In contrast to ‘medicalisation’, 
‘pharmaceuticalisation’ focuses on finding potential conditions that are normal and disease 
free, such as baldness in men or indeed GOR, and marketing them as problems requiring 
pharmaceutical treatment. In the UK direct to consumer advertising by pharmaceutical 
companies is limited to ‘over the counter drugs’ (Medicines and Healthcare Products 
Regulatory Agency, 2012), however the internet is easily accessible, wide ranging and a very 
powerful advertising medium (Fox and Ward, 2008). Furthermore, there has been a steady 
increase in the use of the internet to access and acquire health related information 
(McMullen, 2006; Dumit, 2012). As the internet permeates people’s personal and home life 
it can act as a conduit for health information as well as being a powerful force influencing 
perceptions and changing expectations of parenthood and child care.  
 The data for Scotland show that from 2014 the prescribing rate for alginate started 
to level out, or reach a plateau, although the prescribing rates for both omeprazole and 
ranitidine have continued to rise steadily. As alginate for infants can be readily bought over 
the counter from pharmacies, it may be that more parents are buying the product 
themselves rather than seeking a prescription. In addition, the rising trend in the prescribing 
of omeprazole and ranitidine, may also reflect the stepped-care approach advocated by 
NICE (2015) is not being followed. An earlier European wide survey (Quitadamo et al, 2014) 
involving 11 countries (excluding the UK) found that the 2009 North American Society for 
Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for 
Paediatric Gastroenterology, Hepatology, and Nutrition Guideline (NASPGHAN – ESPGHAN 
Guideline) was not implemented in practice and that 36% of the paediatricians surveyed 
prescribed PPI for infants with symptoms of GOR, and 39% of paediatricians prescribed PPI 
for infants with distressed behaviour and unexplained crying. Commenting on the study 
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(Quitadamo et al, 2014), McCracken (2014) suggests that poor implementation of the 
guideline may be due to ignorance or lack of awareness of the guideline by practitioners, 
particularly if it was not widely published or promoted. It is possible, therefore, that some 
practitioners in Scotland are unaware of the existence of the NICE guideline. Alternatively, 
the guidelines regarding the stepped care approach may be deemed ineffective and 
therefore ignored (McCracken, 2014). This suggests that further research to explore the up-
take and implementation of clinical guidelines by health visitors and general practitioners is 
needed. 
 Regression analysis showed a linear trend, particularly for omeprazole and ranitidine, 
which, if continued, suggests estimated annual increases in the prescribing of omeprazole 
and ranitidine. This is a concern given the uncertain efficacy of these drugs and the potential 
for adverse affects (Kierkus et al, 2014; Tighe et al, 2014; Gieruszczak-Bialek et al, 2015). 
However, also cause for concern is the cost of potentially ineffectual and unnecessary 
prescribing, particularly as NHS services in the UK are reported to be under enormous 
pressure (Lacobucci, 2017; Gullard, 2017) and in Scotland NHS Boards are reported to 
struggle to keep pace with increasing demand and increasing cost (Audit Scotland, 2016). 
Therefore, the drive for efficiency savings in health spending is paramount. Between the 
years ending 2013 and 2015 the cost of drugs in NHS Scotland rose by 10% (Audit Scotland, 
2016) . Therefore, the current evidence regarding the efficacy of these drugs suggests that 
this is an area where efficiency savings could be made, particularly if long term use of these 
drugs in the 0 to 1- year age group leads to unwarranted and adverse effects (Kirekus, et al, 
2014; Gieruszczak-Bialek et al, 2015). 
  
To our knowledge, this study is the first to describe changing patterns of practices and 
prescribing with regard to the management of GOR and GORD in infants aged 0 to 1 year in 
the UK. Previous studies have been undertaken in other countries but different health care 
systems do not allow for direct comparisons.  
 The escalation in prescribing rates of alginate, H2RA, and PPI in the 0 to 1-year age 
group coupled with the uncertain efficacy and lack of evidence to support the use of these 
drugs raises questions for clinicians and policy makers regarding practitioner prescribing 
behaviours, and measures to support families to implement the recommended conservative 
measures when caring for their child. Evidence suggests that conservative measures are 
sufficient in the management of symptoms of GOR in infants (Puntis, 2015, Drug and 
Therapeutics Bulletin, 2010; Onyeador, Paul, and Sandhu, 2010) therefore in Scotland there 
is clearly a role for health visitors to offer additional support to parents, giving them 
confidence to care for their baby and manage the symptoms of GOR conservatively. 
However, further research to provide evidence of the impact of the health visiting service 
and promotion of conservative measures in the management of GOR is needed. 
 While the NICE (2015) guideline advocates a stepped-care approach to the 
management of GOR and GORD in infants starting with conservative measures, the rise in 
the prescribing rates of ranitidine and omeprazole suggest that the recommendations of the 
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guideline are not being followed or adhered. However, as indicated (Quitadamo et al, 2014) 
this may be due to practitioners’ lack of knowledge of the new guidance and therefore there 
is a need for policy makers to raise awareness and promote the NICE (2015) guidance more 
widely. Alternatively, it may be that the recommendations are perceived not to work in 
practice suggesting further research is needed to explore the efficacy and safety of the 
drugs in infants. 
 
Strengths and Limitations 
A strength of the study is that the prescribing data obtained for secondary analysis from ISD 
Scotland is the most accurate, robust and reliable in Scotland (ISD Scotland, 2010). 
However, the study is not without limitations and weaknesses. The first limitation concerns 
the data for alginate or Gaviscon. This may be under-represented as some alginate 
preparations for young infants can be bought over the counter, hence it is possible that the 
use of these medicines are even higher than the ISD Scotland data would infer.  
A second limitation concerns the age of the infants prescribed alginate, omeprazole and 
ranitidine. The ISD Scotland data, do not detail whether the medicines were prescribed 
consistently for 12 months or whether they peaked at set ages. A further limitation 
concerns the reason for prescribing the medicines. Whilst alginate (Gaviscon), H2RA 
(ranitidine) and PPI (omeprazole) are medicines used primarily in the management of GOR 
and GORD, it cannot be assumed that all prescriptions were written in this regard.  
 
 
Conclusion 
Analysis of data from ISD Scotland has identified increased prescribing rates for alginate 
(Gaviscon), H2RA (ranitidine) and PPI (omeprazole) in the 0 to 1-year age group in Scotland, 
as well as significant variation in the patterns of prescribing of these drugs across NHS 
Boards. Given the uncertain efficacy of these drugs, especially the unlicensed drugs 
(ranitidine and omeprazole), this is a concern. Whilst it is acknowledged that the use of 
H2RA and PPI can be beneficial in acid related cases such as GORD or oesophagitis, to 
administer medicines unnecessarily is not only costly to the public purse but arguably 
unethical and not in the best interests of the child. 
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